EUVIMEDEUVIMED entdecken
Übersichtsarbeit

In vivo CAR T cell engineering: design principles and open questions

Amin Aalipour, Ariana Barreiro, Andrea Garmilla, Michael E Birnbaum

Trends in Cancer · 2026

DOI: 10.1016/j.trecan.2026.01.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026. Verfasst von Amin Aalipour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Koch Institute for Integrative Cancer Research, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes, Cell Engineering. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Massachusetts Institute of Technology, Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking, Agency for Science, Technology and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic malignancies, leading to seven FDA-approved products, but widespread adoption has been limited by costly and complex manufacturing and administration. Several methods have emerged to directly reprogram T cells within patients, with the potential to simultaneously improve potency, reduce costs, and broaden accessibility. While early clinical studies demonstrate safety and therapeutic activity, critical questions remain regarding long-term efficacy, the interplay between means of delivery and host biology, and optimal disease indications for each delivery approach. This review summarizes the preclinical and clinical data for state-of-the-art viral and nonviral approaches for in vivo CAR-T engineering, discusses their opportunities and limitations, and highlights key open questions that will shape the maturation of this emerging field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesCell EngineeringHematologic NeoplasmsHumansAnimalsReceptors, Antigen, T-CellGenetic Therapy

Stichwörter der Autor:innen

CAR T celladoptive cell therapyin vivo engineeringlipid nanoparticleoff-the-shelf gene therapytargeted lentivirus

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
  • Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; Singapore-MIT Alliance for Research and Technology Cen…
  • Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Singapore-MIT Alliance for Research and Technology Centre, Singapore, Singapore; Department of Immunology, Harvard Medical School, Boston, MA, USA.

Förderung

  • Massachusetts Institute of Technology
  • Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking
  • Agency for Science, Technology and Research
  • National Research Foundation Singapore

Zitieren

APA

Aalipour, A., Barreiro, A., Garmilla, A., & Birnbaum, M. E. (2026). In vivo CAR T cell engineering: design principles and open questions. Trends in Cancer. https://doi.org/10.1016/j.trecan.2026.01.007

Vancouver

Aalipour A, Barreiro A, Garmilla A, Birnbaum ME. In vivo CAR T cell engineering: design principles and open questions. Trends in Cancer. 2026. doi:10.1016/j.trecan.2026.01.007

BibTeX
@article{Aalipour2026,
  author = {Aalipour, Amin and Barreiro, Ariana and Garmilla, Andrea and Birnbaum, Michael E},
  title = {In vivo CAR T cell engineering: design principles and open questions},
  journal = {Trends in Cancer},
  year = {2026},
  doi = {10.1016/j.trecan.2026.01.007}
}
Kostenlos starten →